Noblis ESI awarded Joint Enterprise-Research Development Acquisition Program contract
Chantilly, VA-based Noblis announced on March 1 that the company’s wholly-owned subsidiary, Noblis ESI, has secured placement on the Joint Program Executive Office for Chemical and Biological Defense’s Joint Enterprise-Research Development Acquisition Program. The $8 billion multi-award Indefinite Delivery/Indefinite Quantity (IDIQ) omnibus vehicle, competitively awarded, will support the JPEO-CBD mission to manage our nation’s investments in chemical, biological, radiological, and nuclear (CBRN) defense equipment.
“Noblis ESI is proud to have the opportunity to expand our footprint in CBRN through this award, which further diversifies our unwavering support of the defense mission,” said Vernon Ingram, president of Noblis ESI. “We look forward to delivering integrated capabilities, along with our team members, that will better enable the warfighter to remain secure and connected regardless of the operational environment.”
With this award, Noblis will provide subject matter experts, capabilities, and contextual experience to support research, development, production, procurement, and fielding of Chemical, Biological, Radiological, and Nuclear (CBRN) defense systems, equipment, and materiel for the Department of Defense.
“The Noblis family of companies provides a wide spectrum of support to the chemical and biological defense mission— from medical countermeasures, to bioinformatics tools, to detection analysis,” said Jordin Cohen, Noblis vice president of defense and homeland security. “Noblis has supported JPEO-CBD since 2009, and we look forward to continuing to ensure that our nation’s warfighters remain capable and protected during all conditions.”